Disclosed Amino Acid Sequence Derived From Parasitic Organism (e.g., Dirofilaria, Eimeria, Trichinella, Etc.) Patents (Class 424/191.1)
  • Patent number: 10363297
    Abstract: Immunogenic compositions containing Escherichia coli 0157:H7 flagella including fusion proteins and methods using the immunogenic compositions are disclosed. Inducing an immune response in an animal to Escherichia coli O157:H7 flagella will result in prevention of colonization by Escherichia coli O157:H7 in the animal or a reduction in the amount of Escherichia coli O157:H7 infecting the animal. The immune composition will prevent or reduce the attachment of Escherichia coli 0157:H7 to cells within the animal.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: July 30, 2019
    Assignees: The University Court of the University of Edinburgh, Moredun Research Institute, SRUC
    Inventors: David Gally, Tom Nathan McNeilly, David George Emslie Smith, Chris Low, Arvind Kumar Mahajan, Stuart W. Naylor
  • Patent number: 10350217
    Abstract: Antimicrobial agents, compositions that include the agent(s) and use(s) thereof are provided. Also disclosed are screening assays for identifying antimicrobial agents.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 16, 2019
    Assignees: University of Massachusetts, Worcester Polytechnic Institute
    Inventors: Paul Kaufman, Jessica Lopes Da Rosa-Spiegler, Reeta Prusty Rao, Ahmed Fazly
  • Patent number: 9907753
    Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: March 6, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Darrell J. Irvine, Jaehyun Moon
  • Patent number: 9889196
    Abstract: A composition includes at least one mineral oil, a surfactant having a hydrophilic property characterized by an HLB value equal to 12 and a divalent inorganic salt intended to be used as an adjuvant in a vaccine composition for the in ovo vaccination of avian species wherein the composition is an oil-in-water emulsion or microemulsion.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: February 13, 2018
    Assignee: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIED CHIMIQUES SEPPIC
    Inventors: Juliette Ben Arous, Laurent Dupuis, Hyun Lillehoj
  • Patent number: 9884101
    Abstract: The present invention relates to recombinant fragments of Plasmodium polypeptides and polynucleotides encoding same. The invention further relates to compositions comprising the recombinant fragments of Plasmodium polypeptides and their use in the treatment and prevention of malaria.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: February 6, 2018
    Assignee: The Walter and Eliza Hall Institute for Medical Research
    Inventors: Lin Chen, Alan Cowman, Tony Triglia
  • Patent number: 9782363
    Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) or an ortholog of AgrA includes administering to the bacterium an amount of a pharmaceutical composition effective to inhibit the synthesis of one or more virulence factors by the bacterium, the pharmaceutical composition including an AgrA antagonist.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: October 10, 2017
    Assignee: Case Western Reserve University
    Inventors: Menachem Shoham, Rajesh Viswanathan, Guanping Yu
  • Patent number: 9750803
    Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles comprise terminal-cysteine-bearing antigens or cysteine-modified antigens, at their surface and/or internally.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: September 5, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Darrell J. Irvine, Jaehyun Moon
  • Patent number: 9675683
    Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: June 13, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Guido Grandi, Renata Maria Grifantini, Oretta Finco
  • Patent number: 9458493
    Abstract: The present invention provides a method of sequencing all or part of a target nucleic acid molecule by determining the sequence of a portion of said nucleic acid molecule in addition to information regarding the position of said portion and in particular provides a new method of sequencing involving the magnification of one or more bases of said bases to aid identification.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: October 4, 2016
    Assignee: Empire IP LLC
    Inventor: Preben Lexow
  • Patent number: 9394316
    Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 19, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Sanjay A. Desai, Ajay D. Pillai
  • Patent number: 9394371
    Abstract: The invention provides an immunogenic molecular entity, a supramolecular assembly, and an antibody that can be used to inhibit Gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a Gram-positive bacterial infection. The invention also provides methods of inhibiting Gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a Gram-positive bacterial infection.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: July 19, 2016
    Assignee: The Scripps Research Institute
    Inventors: Kim D. Janda, Gunnar F. Kaufmann, Junguk Park
  • Patent number: 9382308
    Abstract: An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO: 1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO: 1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO: 13). The immunogens can be used in compositions and in the treatment of disorders.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 5, 2016
    Assignee: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Keith L. Black, Gentao Liu
  • Patent number: 9364539
    Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: June 14, 2016
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Brad J. Spellberg
  • Patent number: 9339533
    Abstract: The present invention relates to new attenuated M. bovis bacteria strains passaged at least 110 times. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of any of those attenuated M. bovis bacteria strain, their manufacture and use for the treatment and prophylaxis of M. bovis infections and combinations with other veterinary vaccines or medicaments.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: May 17, 2016
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Beck, Jeffrey Knittel
  • Patent number: 9314517
    Abstract: Compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream are disclosed herein.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: April 19, 2016
    Assignees: IMPERIAL INNOVATIONS LTD, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: William J. Snell, Yanjie Liu, Oliver Billker, Robert E. Sinden, Rita Tewari
  • Patent number: 9310381
    Abstract: The present invention relates to engineered Clostridium difficile type IV pilin (tfp) genes, type IV pilin proteins which can serve as a diagnostic marker for identification of patients infected with C. difficile, and vaccines comprising type IV pilin proteins, antigenic fragments and variants thereof for therapeutic interventions.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: April 12, 2016
    Assignee: University of Maryland, Baltimore
    Inventor: Michael Donnenberg
  • Patent number: 9296754
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 29, 2016
    Assignee: Novartis AG
    Inventors: Fang Liang, Pranab Kumar Mishra, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Liying Jocelyn Tan, Agnes Vidal
  • Patent number: 9267163
    Abstract: Two or more Neisserial proteins (e.g. A and B) are expressed as a single hybrid protein which can be represented simply by the formula NH2-A-B—COOH.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: February 23, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Maria Aricò, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marzia Monica Giuliani, Mariagrazia Pizza
  • Patent number: 9249202
    Abstract: The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognized by a CD4+ T cell, more specifically, of an allergen or autoantigen, coupled, optionally, through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides may be used for the prevention or treatment of immune disorders, more specifically, of allergic disorders or autoimmune diseases. The present invention thus provides methods of treatment or preventing immune disorders by using such peptides.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: February 2, 2016
    Assignees: Life Sciences Research Partners VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 9149542
    Abstract: The present application relates to microvesicles derived from a protoplast which is a bacterial, arhaea, fungal or plant cell or the like from which a cell wall is removed. The microvesicles derived from a protoplast enables free loading of a material necessary for diagnosis, treatment, vaccine, target induction, cell membrane fusion with a target cell, reduction of in vivo and in vitro side effects, stability improvement, and the like, and allows the therapeutic material, the diagnostic material and/or the vaccine material to be delivered specifically to a specific tissue or cell.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: October 6, 2015
    Assignee: AEON MEDIX INC.
    Inventors: Yong Song Gho, Su Chul Jang, Yoon Keun Kim, Oh Youn Kim
  • Patent number: 9125854
    Abstract: Vaccines comprising fliC and CD 154 polypeptides and Salmonella enteritidis vaccine vectors comprising fliC polypeptides are provided. Also provided arc methods of enhancing an immune response against flagellated bacteria and methods of reducing morbidity associated with infection with flagellated bacteria.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: September 8, 2015
    Assignees: The Board of Trustees of the University of Arkansas, The Texas A&M University System
    Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Sherryll Layton
  • Patent number: 9120869
    Abstract: The disclosure provides compositions that are useful for eliciting a strain-transcending immune response in an animal or human directed against the blood-stage of the malarial parasite Plasmodium vivax. The compositions are based on the ligand domain of Plasmodium vivax Duffy binding protein (PvDBPII). Polar charged polymorphic residues within the dominant strain-specific B-cell epitope were mutated to uncharged residues (e.g. serine, alanine and threonine). This DEKnull variant of PvDBPII produced in bacteria can be purified and refolded in vitro to mimic conformation and erythrocyte binding function of native DBPII. Immunogenicity of DEKnull was confirmed by administration to mice. Compared to the naturally-occurring, strain variant DBPII, DEKnull elicits antibodies that are more broadly reactive with different strain variants of DBPII and enhances production of functional inhibitory antibodies to the shared protective epitopes of native DBPII.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: September 1, 2015
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: John H. Adams, Francis B. Ntumngia, Jesse L. Schloegel, Samantha J. Barnes, Amy M. McHenry, Patchanee Chootong
  • Patent number: 9109040
    Abstract: The present invention relates to polypeptides from Plasmodium and polynucleotides encoding the polypeptides. The invention further relates to compositions comprising the polypeptides and their use in the treatment and prevention of malaria.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: August 18, 2015
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Lin Chen, Alan Cowman, Tony Triglia
  • Patent number: 9068020
    Abstract: An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: June 30, 2015
    Assignee: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Keith L. Black, Gentao Liu
  • Publication number: 20150147349
    Abstract: This invention relates to compositions and methods for eliciting an immune response against a parasite of the genus Plasmodium in a mammal.
    Type: Application
    Filed: February 15, 2013
    Publication date: May 28, 2015
    Inventors: Timothy A. Springer, Chafen Lu, Gaojie Song, Adem Koksal
  • Patent number: 9028843
    Abstract: The present invention provides a vaccine for preventing and/or treating Plasmodium falciparum infections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant. X1-A-B-X2-Y-X3-(Y)n-X4-(Y)n-X5??(1) (In the formula, X1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X2 represents the 73th to 177th amino acid residues; X3 represents the 178th to 258th amino acid residues; X4 represents the 259th to 289th amino acid residues; X5 represents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1).
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: May 12, 2015
    Assignee: Osaka University
    Inventors: Toshihiro Horii, Ken Ishii, Takahiro Tougan
  • Publication number: 20150125483
    Abstract: This invention is directed to methods for the production of immunogenic granular particles. In certain embodiments, the invention is directed to methods and products for the production immunogenic granular particles produced in ciliates. In certain embodiments, the invention is directed to compositions comprising Grl/Ag fusion polypeptides.
    Type: Application
    Filed: May 29, 2012
    Publication date: May 7, 2015
    Applicant: Tetragenetics, Inc.
    Inventors: Theodore G. Clark, Yelena Bisharyan, Ashot Papoyan, Kyle Anderson, Paul Colussi
  • Publication number: 20150125482
    Abstract: The invention relates to a recombinant polypeptide construct comprising epitopes from Plasmodium falciparum protein circumsporozoite protein (CSP). The epitopes contain HLA class I binding motifs and stimulate an anti-malaria CD8+ T-cell response. The polypeptides can be incorporated into immunogenic formulations against malaria. Additionally, the antigens are useful for facilitating evaluation of immunogenicity of candidate malaria vaccines.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 7, 2015
    Inventors: Martha Sedegah, Thomas Richie
  • Patent number: 9017699
    Abstract: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: April 28, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Publication number: 20150093408
    Abstract: The present invention relates to a Lyme disease vaccine, a genetic construct, recombinant protein, method for genetic construct design, method for vaccine delivery, method for recombinant proteins delivery, use of recombinant proteins in the production of Lyme disease vaccine. In particular, the method concerns the use of TROSPA and TROSPA-Salp15 recombinant proteins derived from castor bean tick (Ixodes riccinus) as a component of Lyme disease vaccine for animals. The antibodies present in blood of an immunized vertebrate directed against the TROSPA proteins considerably reduce the chance of infecting new ticks by blocking or hindering the interaction of TROSPA protein with OspA protein of Borrelia burgdorferi sensu lato. The interaction is crucial in the process of the spirochete entering a tick.
    Type: Application
    Filed: October 21, 2013
    Publication date: April 2, 2015
    Inventors: Anna Urbanowicz, Marek Figlerowicz, Dominik Lewandowski
  • Publication number: 20150086583
    Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 26, 2015
    Inventors: Rosa A. Maldonado, Carylinda Serna, Igor C. Almeida
  • Publication number: 20150079126
    Abstract: The invention relates to antigens, associated with sterile immunity, and methods of their use, in an immunogenic formulation to confer an immune response against Plasmodium falciparum. The inventive antigens were identified by their association with sterile immunity against malaria.
    Type: Application
    Filed: September 16, 2013
    Publication date: March 19, 2015
    Inventors: Denise Doolan, Angela Trieu, Phillip L. Felgner
  • Publication number: 20150079127
    Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 19, 2015
    Inventors: Theodorus Petrus Maria Schetters, Karina Moubri-Menage, Jos Kleuskens, Andreas Walter Claudius Rohwer
  • Publication number: 20150071876
    Abstract: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 12, 2015
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Reinhard GLUECK, Agata FAZIO, Viviana GIANINO, Martin A. BILLETER
  • Patent number: 8968750
    Abstract: The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: March 3, 2015
    Assignee: Ruprecht-Karls-Universität Heidelberg
    Inventors: Ann-Kristin Mueller, Eva Morath
  • Publication number: 20150056243
    Abstract: A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more polynucleotides including the regions codifying one or more immunogenic polypeptides, or a monocomponent vaccine comprising at least one component selected among an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of them and a group of polynucleotides including the regions codifying one or more immunogenic polypeptides derived from Trypanosoma cruzi and pharmaceutical compositions containing said multicomponent and monocomponent vaccines, the procedures for obtaining the immunogen portion of said vaccines and the nucleic acid used in the procedure.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 26, 2015
    Inventor: Carlos de Baeremaecker Barros
  • Publication number: 20150037365
    Abstract: The present invention provides a vaccine for preventing and/or treating Plasmodium falciparum infections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant. X1-A-B-X2-Y-X3-(Y)n-X4-(Y)n-X5??(1) (In the formula, X1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X2 represents the 73th to 177th amino acid residues; X3 represents the 178th to 258th amino acid residues; X4 represents the 259th to 289th amino acid residues; X5 represents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1.
    Type: Application
    Filed: July 8, 2014
    Publication date: February 5, 2015
    Inventors: Toshihiro HORII, Ken ISHII, Takahiro TOUGAN
  • Publication number: 20150040251
    Abstract: The present invention is based upon the identification of a number of antigens derived from species of the genus Teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more Teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate Teladorsagia infections/infestations.
    Type: Application
    Filed: February 4, 2013
    Publication date: February 5, 2015
    Inventors: Jacqueline Matthews, Alasdair Justice Nisbet, David Knox
  • Publication number: 20150037366
    Abstract: A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby reduce or alleviate inflammation in the subject. A method for preventing or treating asthma or inflammatory bowel disease in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby prevent or treat asthma or inflammatory bowel disease in the subject. The subject may be a mammal, inclusive of humans.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 5, 2015
    Applicant: JAMES COOK UNIVERSITY
    Inventors: Alex Loukas, Severine Navarro
  • Publication number: 20150017200
    Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.
    Type: Application
    Filed: May 23, 2014
    Publication date: January 15, 2015
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Ajay BHATIA, Steven G. REED
  • Publication number: 20150004099
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Application
    Filed: February 8, 2013
    Publication date: January 1, 2015
    Applicant: VAR2 PHARMACEUTICALS APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • Publication number: 20140377299
    Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.
    Type: Application
    Filed: August 4, 2014
    Publication date: December 25, 2014
    Applicant: LIFE SCIENCES RESEARCH PARTNERS VZW
    Inventor: Jean-Marie SAINT-REMY
  • Patent number: 8916167
    Abstract: The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula Ab-X where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: December 23, 2014
    Assignee: Purdue Research Foundation
    Inventors: Philip S. Low, Mary J. Turk
  • Patent number: 8911746
    Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: December 16, 2014
    Assignee: Infectious Disease Research Institute
    Inventors: Yasuyuki Goto, Steven G. Reed
  • Publication number: 20140356391
    Abstract: Polypeptides comprising amino acid sequences of particulate antigens isolated from various species of Leishmania protozoa, or immunogenic variants thereof, are disclosed for the treatment and clinical remission of cutaneous leishmaniasis, psoriasis, psoriatic arthritis, rheumatoid arthritis, atopic dermatitis, seborrheic dermatitis and skin papilloma. Also disclosed are nucleic acid sequences encoding such polypeptides, vectors incorporating such nucleic acid sequences, methods for genetically engineering microbial host cells to produce such polypeptides, and such recombinant microbial host cells. The polypeptides induced a TH1 cellular immune response, a positive intradermic reaction, and a blastogenic response in peripheral blood lymphocytes after clinical remission of lesions.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 4, 2014
    Inventor: Jose Antonio O'Daly
  • Publication number: 20140348870
    Abstract: Contemplated compositions and methods employ selected antigens form Plasmodium falciparum and can be used as a vaccine, therapeutic agent, and/or diagnostic tool. Especially preferred antigens are post-challenge immunity associated antigens that are identified via pre-infection suppressive treatment, controlled sub-symptomatic infection to develop immunity, and comparative proteomic differential analysis.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 27, 2014
    Inventors: Philip L. Felgner, Xiaowu Liang, Robert Sauerwein
  • Publication number: 20140341918
    Abstract: The invention provides compositions and methods for preventing or reducing the severity of malaria.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 20, 2014
    Inventors: Jonathan Kurtis, Christian Parcher Nixon, Dipak Kumar Raj, Jennifer Frances Friedman, Michal Fried, Patrick Emmet Duffy
  • Publication number: 20140322257
    Abstract: The present invention refers to recombinant DNA molecules codifying fused peptides from different allergens from Blomia tropicalis and Dermatophagoides pteronyssinus having potential usefulness in prevention and treatment of allergies caused by domestic mites. Specifically, the invention discloses fusion proteins composed by different fragments of allergens Der p 1, Der p 2, Der p 7, Der p 8, Blo t 5, Blo t 8, Blo t 18, Blo t 12 and Blo t 13 with reduced serum IgE reactivity in allergic and non allergic individuals. It also discloses methods for production of these molecules in an expression system based on E. coli and purification. The invention refers also to effective and safe vaccines.
    Type: Application
    Filed: September 20, 2012
    Publication date: October 30, 2014
    Applicant: UNIVERSIDAD DE CARTAGENA
    Inventors: Leonardo Puerta Llerna, Luis Caraballo, José Fernando Cantillo
  • Publication number: 20140271702
    Abstract: Compositions of either the aquaporin protein from the cattle tick, Rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this aquaporin protein, are effective for eliciting a protective immune response against other tick species in non-bovine animals. The R. microplus aquaporin protein is antigenic and can be administered as a protein vaccine, or in the alternative, the nucleic acid construct can be utilized as a DNA vaccine. Induction of the immune response significantly reduces or eliminates the infestation of treated, non-bovine animals with ticks other than the cattle tick, particularly the brown dog tick, Rhipicephalus sanguineus. Moreover, as ticks are vectors of a variety of pathogenic agents, the reduction in the incidence of tick infestation afforded by the vaccines may concurrently reduce the incidence of diseases caused by these pathogenic agents in susceptible animals.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Inventors: Felicito Guerrero, Adalberto A. Perez De Leon, Lane D. Foil
  • Publication number: 20140271656
    Abstract: Immunologically active agents are described, including isolated Pneumocystis A 12 protein or polypeptides; immunogenic conjugates containing Pneumocystis A 12 protein or polypeptide of the present invention; antibodies recognizing the Pneumocystis A 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the Pneumocystis A 12 protein or polypeptide of the present invention, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a subject.
    Type: Application
    Filed: August 6, 2012
    Publication date: September 18, 2014
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Francis Gigliotti, Terry W. Wright, Constantine G. Haidaris, Patricia J. Simpson-Haidaris